Skip to main content
SpringerLink
Log in

Late relapsing mantle cell lymphoma showing preserved sensitivity to single-agent lenalidomide

  • Case Report
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Mantle cell lymphoma is a hematologic malignancy characterized by poor therapeutic outcomes. Immunomodulatory drugs are a focus of attention in this disease, especially for the elderly and frail patients not able to tolerate the typically intensive therapeutic approaches used in fitter patients. We here present the case of refractory mantle cell lymphoma of the elderly that achieved complete remission following the use of single-agent lenalidomide, and a second complete response to the same regimen on relapse 5 years later.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Swerdlow SH. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: WHO Press; 2008.

    Google Scholar 

  2. Cheah CY, Seymour JF, Wang ML. Mantle cell lymphoma. J Clin Oncol. 2016;34:1256–69.

    Article  PubMed  Google Scholar 

  3. Tempescul A, Ianotto JC, Morel F, Marion V, De Braekeleer M, Berthou C. Lenalidomide, as a single agent, induces complete remission in a refractory mantle cell lymphoma. Ann Hematol. 2009;88(9):921–2.

    Article  PubMed  Google Scholar 

  4. Vose JM. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 2015;90(8):739–45.

    Article  CAS  PubMed  Google Scholar 

  5. Witzens-Harig M, Hess G, Atta J, Zaiss M, Lenz G, Scholz C, et al. Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting. Ann Hematol. 2012;91(11):1765–72.

    Article  CAS  PubMed  Google Scholar 

  6. Mussetti A, Kumar A, Dahi PB, Perales MA, Sauter CS. Lifting the mantle: unveiling new treatment approaches in relapsed or refractory mantle cell lymphoma. Blood Rev. 2015;29(3):143–52.

    Article  PubMed  Google Scholar 

  7. Avivi I, Goy A. Refining the mantle cell lymphoma paradigm: impact of novel therapies on current practice. Clin Cancer Res. 2015;21(17):3853–61.

    Article  CAS  PubMed  Google Scholar 

  8. Weisel K, Kanz L. Lenalidomide. Recent Results Cancer Res. 2014;201:347–57.

    Article  CAS  PubMed  Google Scholar 

  9. Kritharis A, Coyle M, Sharma J, Evens AM. Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities. Blood. 2015;125(16):2471–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Habermann TM, Lossos IS, Justice G, Vose JM, Wiernik PH, McBride K, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol. 2009;145(3):344–9.

    Article  CAS  PubMed  Google Scholar 

  11. Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. Ann Oncol. 2011;22(7):1622–7.

    Article  CAS  PubMed  Google Scholar 

  12. Goy A, Sinha R, Williams ME, Kalayoglu Besisik S, Drach J, Ramchandren R, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013;31(29):3688–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

Drs. Bagacean, Bocsan and Zdrenghea are supported by a grant of the Romanian National Authority for Scientific Research and Innovation, CNCS-UEFISCDI, Project Number PN-II-RU-TE-2014-4-2074.

Author information

Authors and Affiliations

  1. Institute of Cancerology and Hematology, University Hospital, Brest, France

    Adrian Tempescul & Jean-Christophe Ianotto

  2. Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

    Cristina Bagacean, Corina Bocsan & Mihnea Zdrenghea

  3. Laboratory of Immunology and Immunotherapy, University Hospital, Brest, France

    Cristina Bagacean

  4. Nuclear Medicine Department, University Hospital, Brest, France

    Pierre-Yves Salaun

  5. Ion Chiricuta Oncology Institute, Cluj-Napoca, Romania

    Mihnea Zdrenghea

Authors
  1. Adrian Tempescul
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jean-Christophe Ianotto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cristina Bagacean
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pierre-Yves Salaun
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Corina Bocsan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mihnea Zdrenghea
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mihnea Zdrenghea.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Informed consent

The patient gave her informed consent for the usage of clinical data for scientific purposes.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tempescul, A., Ianotto, JC., Bagacean, C. et al. Late relapsing mantle cell lymphoma showing preserved sensitivity to single-agent lenalidomide. Int J Hematol 104, 400–402 (2016). https://doi.org/10.1007/s12185-016-2020-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-016-2020-4

Keywords

Search

Navigation